Over-expressing iNOS predicts aggressive clinicopathologic characteristics and poor survival outcome of ovarian cancer patients, supporting the idea of iNOS expression as a useful prognostic marker for patients with ovary cancer. Here, NOS2 is linked to ovarian carcinoma.